Date post: | 27-Jul-2016 |
Category: |
Documents |
Upload: | center-for-disease-dynamics-economics-policy |
View: | 229 times |
Download: | 4 times |
The National Geographic Society
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
1 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
2 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
3 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
4 of 20 3/14/2016 11:20 AM
A Blog by Maryn McKenna
BLOGGERS
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
5 of 20 3/14/2016 11:20 AM
Governments must help solve the problem of no new antibiotics by funding and creating
incentives for developing new drugs, almost 100 pharmaceutical companies and trade
associations say in a statement being released this evening at the World Economic Forum
in Davos.
“The value assigned to antibiotics and diagnostics often does not reflect the benefits they
bring to society, nor the investment required for their creation,” they say. “We call on
governments to commit to allocating the funds needed to create a sustainable and
predictable market for these technologies while also implementing the measures needed
to safeguard the effectiveness of antibiotics.”
The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
6 of 20 3/14/2016 11:20 AM
Combating Antimicrobial Resistance commits the companies—which include both the
largest, such as Merck & Co. and Pfizer Inc., and many small biotech firms and makers of
diagnostic devices—to a common set of global actions to combat resistance. Those include
reducing overuse, encouraging the development of diagnostic devices that can keep the
drugs from being overused, and conserving antibiotics in a manner generally called
“stewardship”—which, by keeping critically needed drugs on the shelf, can cut into
company profits. And it calls for governments and others funders to join the companies
in pursuing new drugs to solve what’s known as the “pipeline problem.” That is the
difficult reality that antibiotics manufacturers practically abandoned the field after about
2000, because the relatively low retail prices of their drugs (compared to cancer drugs, for
instance), coupled with the advance of antimicrobial resistance, turned making
antibiotics into an unrewarding move.
Since the Infectious Diseases Society of America flagged the problem of “bad bugs, no
drugs” in a revelatory report 12 years ago, policy makers have argued over how best to
lure drugmakers back into the market, proposing price hikes, patent extensions, prizes,
up-front payments, and a variety of other incentives. What should be offered to
companies to bring them back is a matter of intense debate, captured in this issue brief by
the Center for Disease Dynamics, Economics and Policy and this Chatham House
analysis by Kevin Outterson of Boston University. The issue is at the heart of three pieces
of legislation, the GAIN Act of 2012, the ADAPT Act of 2013, and the PATH Act,
introduced in the current Congress. Last summer, the Review on Antimicrobial
Resistance, a two-year project created by UK Prime Minister David Cameron
to investigate solutions to the global crisis, proposed a program of supports for innovation
and early-stage research, and also mammoth payments that would effectively free a
company from having to earn its investment back via sales.
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
7 of 20 3/14/2016 11:20 AM
The declaration made this evening (Thursday morning, in Europe) will be housed on the
site belonging to the Review on Antimicrobial Resistance — but its chairman, economist
Lord Jim O’Neill, said in an interview that it should not be construed as the Review’s
work. “This is a statement coming from industry,” he told me. “We are pleased to see it
happen. But our own final recommendations, which are 4-5 months off, may differ. Part
of their declaration is a call to governments to give them the incentives they want. But
it might well be that in the range of recommendations we make will be that the industry
itself may have to make significant contributions.”
The declaration does not specify which incentives the industry prefers to receive, though
it mentions the lump-sum purchases examined by the Review, technically called market
entry rewards; “insurance-like purchase models”; and enhanced intellectual property
protections. It also does not mention any numbers. But it suggests increases in
reimbursement for antibiotic and diagnostic-device purchases—while being careful to
mention that entities should not be rewarded “for prescribing of antibiotics in greater
volumes” (which would raise company income but increase the risk of resistance).
Dr. John Rex, a senior vice president and chief strategy officer at drugmaker AstraZeneca
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
8 of 20 3/14/2016 11:20 AM
Inc. and one of the strategists behind the declaration, told me:
“The irresolvable tension is, if we prevent the spread of resistance, we won’t use the drugs
very much. And if the revenue to the manufacturer depends on sales for use to
treat infections, the manufacturer doesn’t have any revenue, doesn’t recoup costs and
can’t maintain its supply chain. So I come back to two fundamental questions: What is
antibiotics’ value, and how should we buy them?
“As a metaphor for value, I think of the fire department. We are surrounded by
fire-prevention services: smoke detectors, fire stations, firemen, the water supply. Most of
us never have the misfortune of needing them, but in a very real sense we use them every
day. You would not stop paying for them because you haven’t used them; at the end of the
year, you are delighted not to have. Antibiotics in the hospital are like the fire department.
They have a value when we treat an infection, but they have a bigger value when you know
that you could use them to treat an infection if you needed.”
But how that value is to be priced, and what the mechanisms will be, “will be a project of
some years,” Rex said, adding that some incentives will work better in different
economies or jurisdictions than others. “I’m looking at the operational goal,” he said.
“You don’t start setting up the fire service when the building is already on fire.”
Early reaction tonight to the declaration was enthusiastic but cautious. Ramanan
Laxminarayan, the founder of the Center for Disease Dynamics, Economics and Policy
—which argues that incentives for new drugs should take a back seat to programs to
conserve existing ones—told me by email: “This is a big moment, and a recognition by
industry of the huge role they play in conserving the effectiveness of antibiotics we have
and in the development of the drugs, vaccines and diagnostics we need. But resources
allocated to these needs are still too small, and need to match the scale of the
antimicrobial resistance challenge.”
At the Pew Charitable Trusts, which operates projects on antibiotic resistance and
innovation, senior director of health programs Allan Coukell said: “Antibiotic resistance is
one of the pressing public health issues of our time. This declaration, with its long list of
industry signers, affirms not just the need to tackle the scientific and economic barriers to
drug development, but the importance of conserving the antibiotics we have today.”
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
9 of 20 3/14/2016 11:20 AM
Previous posts:
Dec. 7, 2015: “Proposal: Set International Targets for Farm Antibiotic Use“
Sept. 9, 2015: “Can Offering a $12 Million Prize Make a Difference to Drug
Resistance?“
May 23, 2015: “We Need Antibiotics. They’re Not Profitable to Make. Who Pays?“
Feb. 5, 2015: “How to Fight Superbugs: Start Spending Money“
Dec. 15, 2014: “The Coming Cost of Superbugs: 10 Million Deaths Per Year“
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
10 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
11 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
12 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
13 of 20 3/14/2016 11:20 AM
It looked like the sun was erupting during last week's solar eclipse.
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
14 of 20 3/14/2016 11:20 AM
by Nadia Drake
Amber gives us a detailed look at the oldest chameleon yet found.
by Brian Switek
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
15 of 20 3/14/2016 11:20 AM
The terrifying 'drop bear' is an urban legend, but Australia really was home to a koala cousin that wasnot so cuddly.
by Brian Switek
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
16 of 20 3/14/2016 11:20 AM
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
17 of 20 3/14/2016 11:20 AM
Embed View on Twitter
Tweets by @marynmck
1h
2h
this package is the greatest thing.
twitter.com/verge/status/7…
scored the @glossier phase 2 set.
day, accomplished.
Maryn McKenna Retweeted
Maryn McKenna
@marynmck
Maryn McKenna
@marynmck
Virginia Hughes
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
18 of 20 3/14/2016 11:20 AM
National Geographic
GeneralShopContact
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
19 of 20 3/14/2016 11:20 AM
Follow Nat Geo
Pharma Industry Calls on Governments to Fund New Antibiotics – Phe... http://phenomena.nationalgeographic.com/2016/01/20/davos-declaration/
20 of 20 3/14/2016 11:20 AM